Memed S/A
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Memed S/A - overview
Established
2012
Location
Sao Paulo, Sao Paulo, Brazil
Primary Industry
Software
About
Based in Brazil, Memed specializes in a digital prescription platform that enhances the healthcare experience by facilitating efficient communication between healthcare providers and patients. Memed operates a digital prescription solution that connects healthcare professionals with patients to streamline prescription issuance. Founded in 2012 in Sao Paulo, Brazil, by Marcel Ribeiro and René Moraes, the company has completed a total of four deals. Its latest funding round, a Series C, raised BRL 100 million on December 30, 2021, led by Temasek Holdings along with participation from DNA Capital, Apis Partners, and Just Fit Participações em Empreendimentos S.
A. The total amount raised to date is BRL 100 million. Memed's core product is a digital prescription platform designed to streamline the interaction between healthcare providers and patients. This platform allows physicians to issue electronic prescriptions efficiently, ensuring that patients have easy access to their medications and related healthcare services.
The service fosters a closer relationship between doctors and patients by facilitating preventive care and holistic treatment options, which includes scheduling tests and obtaining medications promptly. Memed's technology is actively utilized by over 262,000 registered healthcare professionals and more than 350 partner organizations across various sectors of the healthcare ecosystem, including pharmacies, hospitals, and clinics. The primary geographical market for Memed's services spans across Brazil, where it significantly enhances the digital healthcare experience for patients and providers alike. Memed generates revenue through partnerships with healthcare providers, pharmacies, and pharmaceutical companies, leveraging a subscription model for its services and technology solutions.
Transactions typically occur when physicians issue digital prescriptions via the Memed platform, which patients can then use to purchase medications directly from affiliated pharmacies. Revenue streams also come from collaborations with health insurance operators that integrate Memed’s technology into their systems to improve service delivery. This collaborative ecosystem enhances the overall efficiency of healthcare delivery in Brazil while ensuring a secure and ethical connection between stakeholders. The financial arrangements with partners often involve programmatic fees or commissions for services rendered, thereby creating a sustainable business model aligned with the digital transformation of healthcare in the region.
In December 2021, Memed raised BRL 100 million in Series C funding led by Temasek Holdings. The company plans to utilize this funding to accelerate growth and expand its digital prescription services. Future initiatives include the development of new products aimed at enhancing features for healthcare professionals and patients. Memed also has strategies in place to expand into new geographic markets, targeting additional regions in Brazil and potentially exploring international opportunities in the coming years.
Current Investors
DNA Capital, Redpoint eVentures, Temasek Holdings
Primary Industry
Software
Sub Industries
Medical Software, Analytics & Performance Software
Website
www.memed.com.br
Verticals
Cloud Computing, HealthTech, Mobile Apps
Total Amount Raised
Subscriber access only
Memed S/A - employee data


Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.